Table 3 Cycle 1 and cumulative TADs of the target lesions

Cycle 1 TAD_max (Gy)

42.3 [5.5–120.3]

IQR: 21.9–76.4

38.9 [3.7–179.5]

IQR: 19.8–69.8

32.7 [8.6–84.8]

IQR: 23.1–59.2

46.5 [3.7–179.5]

IQR: 32.5–79.1

19.7 [12.2–38.9]

IQR: 15.0–26.6

Cycle 1 TAD_peak (Gy)

38.2 [5.0–108.6]

IQR: 19.9–69.5

33.7 [3.3–167.1]

IQR: 17.9–64.3

30.2 [7.5–78.8]

IQR: 21.6–55.4

41.6 [3.3–167.1]

IQR: 27.3–73.5

17.4 [10.9–33.7]

IQR: 13.6–23.8

Cycle 1 TAD₄₁ (Gy)

26.1 [3.6–74.8]

IQR: 13.2–46.8

23.8 [2.3–110.5]

IQR: 12.5–42.7

18.6 [5.7–47.5]

IQR: 14.8–35.3

28.4 [2.3–110.5]

IQR: 19.6–44.5

12.5 [7.6–23.8]

IQR: 9.4–16.4

Cumulative TAD_max (Gy)

127.5 [36.6–271.9]

IQR: 70.9–190.6

122.4 [17.6–329.7]

IQR: 63.0–181.7

110.3 [26.0–234.9]

IQR: 69.1–179.9

149.6 [17.6–329.7]

IQR: 91.2–214.8

55.6 [28.8–90.0]

IQR: 44.7–69.5

Cumulative TAD_peak (Gy)

113.9 [33.8–253.7]

IQR: 64.4–171.9

112.3 [14.5–298.2]

IQR: 56.1–166.2

101.3 [23.3–217.8]

IQR: 64.1–166.2

132.4 [14.5–298.2]

IQR: 86.4–187.9

48.3 [26.9–79.3]

IQR: 40.0–61.2

Cumulative TAD₄₁ (Gy)

77.9 [23.8–170.2]

IQR: 43.4–117.7

70.6 [10.9–208.7]

IQR: 37.3–111.3

62.9 [16.2–142.0]

IQR: 43.2–107.3

91.0 [10.9–208.7]

IQR: 57.9–130.2

34.4 [18.2–55.5]

IQR: 28.3–42.0